next-generation multitarget stool dna test Search Results


next-generation multitarget fecal dna test  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals next-generation multitarget fecal dna test
Next Generation Multitarget Fecal Dna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+multitarget+stool+dna+test/pm40610389-148-7-8?v=MultiTarget+Pharmaceuticals
Average 90 stars, based on 1 article reviews
next-generation multitarget fecal dna test - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
stool dna test  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals stool dna test
Stool Dna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+multitarget+stool+dna+test/pmc11707428-0-28-29?v=MultiTarget+Pharmaceuticals
Average 90 stars, based on 1 article reviews
stool dna test - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
stool dna cologuard plus  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals stool dna cologuard plus
Screening, diagnostic, and prognostic biomarkers, with the method used, sensitivity, specificity, and HR.
Stool Dna Cologuard Plus, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+multitarget+stool+dna+test/pmc11546354-1-1-2?v=MultiTarget+Pharmaceuticals
Average 90 stars, based on 1 article reviews
stool dna cologuard plus - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
multitarget stool dna  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals multitarget stool dna
Screening, diagnostic, and prognostic biomarkers, with the method used, sensitivity, specificity, and HR.
Multitarget Stool Dna, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+multitarget+stool+dna+test/pmc11546354-73-7-8?v=MultiTarget+Pharmaceuticals
Average 90 stars, based on 1 article reviews
multitarget stool dna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
next-generation mt-sdna test  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals next-generation mt-sdna test
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Next Generation Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+multitarget+stool+dna+test/pmc11401593-148-55-13?v=MultiTarget+Pharmaceuticals
Average 90 stars, based on 1 article reviews
next-generation mt-sdna test - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
blood based test shield tm  (Guardant Health)
86
Guardant Health blood based test shield tm
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Blood Based Test Shield Tm, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+multitarget+stool+dna+test/pmc12682382-50-81-85?v=Guardant+Health
Average 86 stars, based on 1 article reviews
blood based test shield tm - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
oc auto fit  (Polymedco inc)
90
Polymedco inc oc auto fit
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Oc Auto Fit, supplied by Polymedco inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+multitarget+stool+dna+test/pm39556364-62-31-35?v=Polymedco+inc
Average 90 stars, based on 1 article reviews
oc auto fit - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Screening, diagnostic, and prognostic biomarkers, with the method used, sensitivity, specificity, and HR.

Journal: International Journal of Molecular Sciences

Article Title: Biomarkers in Colorectal Cancer: Actual and Future Perspectives

doi: 10.3390/ijms252111535

Figure Lengend Snippet: Screening, diagnostic, and prognostic biomarkers, with the method used, sensitivity, specificity, and HR.

Article Snippet: , Next-generation multitarget stool DNA (Cologuard Plus) [ ] , LASS4, LRRC4, PPP2R5C, ZDHHC1, and hemoglobin immunoassay , 94% (87.1–97.7) , 90.6% (90.1–91.0) , -.

Techniques: Diagnostic Assay, Biomarker Discovery, Multiplex PCR, Multiplex Assay, Antigen Assay

Screening, diagnostic, and prognostic biomarkers, with the method used, sensitivity, specificity, and HR.

Journal: International Journal of Molecular Sciences

Article Title: Biomarkers in Colorectal Cancer: Actual and Future Perspectives

doi: 10.3390/ijms252111535

Figure Lengend Snippet: Screening, diagnostic, and prognostic biomarkers, with the method used, sensitivity, specificity, and HR.

Article Snippet: The study of over 20,000 participants using next-generation multitarget stool DNA accomplished all the end-points of the study design, with a sensitivity of 94% (95% CI, 87.1–97.7), and a specificity for advanced neoplasia of 90.6% (95% CI, 90.1–91.0); while independent FIT scored 67.3% (95% CI 57.1–76.5) in sensitivity and 94.8% (95% CI 94.4–95.1) in terms of specificity for advanced neoplasia [ ].

Techniques: Diagnostic Assay, Biomarker Discovery, Multiplex PCR, Multiplex Assay, Antigen Assay

ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Journal: Gastro Hep Advances

Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

doi: 10.1016/j.gastha.2024.05.002

Figure Lengend Snippet: ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Techniques:

Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the First-Generation mt-sDNA Test in the DeeP-C Test Set

Journal: Gastro Hep Advances

Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

doi: 10.1016/j.gastha.2024.05.002

Figure Lengend Snippet: Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the First-Generation mt-sDNA Test in the DeeP-C Test Set

Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Techniques: